With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.
Back
Updates in Cutaneous Lupus Erythematosus from AAD 2026
Expert perspectives from the floor at the American Academy of Dermatology 2026 annual meeting on news and updates in cutaneous lupus erythematosus.
Updates in Cutaneous Lupus Erythematosus from AAD 2026
Episodes
All
All
Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.
Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.
Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.
Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.
Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5